Clinical-stage biopharmaceutical company developing treatments for genetic diseases.
Larimar Therapeutics, Inc. is a pioneering clinical-stage biotechnology company that specializes in the development of innovative treatments for rare diseases. Central to its mission is the utilization of a groundbreaking cell penetrating peptide technology platform. This platform serves as the cornerstone for advancing therapies that target rare and debilitating genetic conditions, addressing significant unmet medical needs within these underserved patient populations.
At the forefront of Larimar Therapeutics' pipeline is its lead product candidate, CTI-1601, currently undergoing Phase 1 clinical trials. CTI-1601 represents a promising advancement in the treatment landscape for Friedreich's ataxia, a rare genetic disorder characterized by progressive neurological deterioration. By focusing on this devastating disease, Larimar Therapeutics aims to introduce therapies that offer hope and potential improvement in quality of life for affected individuals.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics is strategically positioned within a vibrant biotechnology hub. The company's commitment to research and development is complemented by its collaborative approach, forging partnerships and alliances aimed at accelerating the progression of therapeutic candidates through clinical development and regulatory pathways.
Founded on a dedication to scientific innovation and patient-centric care, Larimar Therapeutics continues to expand its capabilities and portfolio. With a deep-rooted passion for addressing rare diseases and a focus on transforming scientific discoveries into tangible treatments, the company remains steadfast in its pursuit of pioneering therapies that make a meaningful impact on patients' lives worldwide.